globenewswire.com · Nov 20, 2025
RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties
Glen Rock, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (RespireRx or the Company), and its subsidiaries, EndeavourRx LLC (EndeavourRx) and ResolutionRx Ltd (ResolutionRx), collectively, the RespireRx Group, leaders in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, today provides a progress and status report to its stockholders, stakeholders, strategic partners as well as other interested parties.
